Back to News
Market Impact: 0.4
Novartis Halts Trials For Rap-cel Immunotherapy Following Deaths From Severe Immune Reaction
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsRegulation & LegislationLegal & Litigation
Novartis has reportedly paused eight clinical trials of rap-cel, a CD19 CAR-T therapy, after three patient deaths in the studies. The deaths appear linked to a severe immune reaction, raising safety concerns for the program. The pause is likely to weigh on sentiment around development timelines and regulatory prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
NVS-0.95
More News
- Indonesia stocks suffer biggest daily slump since 1998 as MSCI weighs downgrade
- ‘I told you so’: China’s chip sector is making breakthroughs—and U.S. export controls are the reasons why
- UK's Healey Plans to Raise Bank Taxes
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- Hybe shares jump 10% as K-pop sensation BTS' tour lifts earnings hopes
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI